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Abstract
Some biological properties of new bifunctional conjugates designed for drug targeting were evaluated through in vitro
experiments. Eight peptidylcyclodextrin compounds were used, which correspond to modified L- or Q-cyclodextrin (CD)
grafted on neuropeptide substance P (SP) or a shorter derivative (SP(4^11)). Using anti-SP and anti-CD antibodies as
molecular probes, we showed that the main structural features of the two moieties of these adducts were preserved. Binding
experiments, using CHO cells expressing the human SP-specific NK1 receptor, demonstrated the functionality of all
peptidylcyclodextrin derivatives, which exhibited IC50 values in a 1039^1037 M range. All compounds were able to induce a
pharmacological response, triggering phosphatidylinositol turnover with EC50 values in the same range as the natural ligand.
Moreover, autoradiography analysis of rat spinal corn sections proved that [125I]SP binding was dose-dependently displaced
by one selected compound (a Q-CD^SP), showing a similar affinity of this adduct for the rat neurokinin 1 receptor. Our
observations demonstrate that these peptidylcyclodextrins efficiently target NK1 receptor-expressing cells. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Drug targeting, e.g., directing a drug towards spe-
ci¢c biological sites, can be achieved in a variety of
ways and has been extensively studied [1]. One of the
commonest approaches is to build a bifunctional
compound, comprising the drug molecule covalently
bound to a signal molecule, which speci¢cally targets
the drug to a relevant site [2^5]. However, these mo-
lecular constructs might result in structural or chem-
ical modi¢cations of the drug, leading to a decrease
in its e⁄ciency. Moreover, each drug requires the
synthesis of a speci¢c compound, which is often dif-
¢cult to achieve. An alternative approach would con-
sist in grafting a signal molecule, a peptide for in-
stance, on a carrier compound capable of
transporting many drug molecules. In this study,
the macrocyclic components cyclodextrins (CDs)
were chosen as carriers, due to their recognized prop-
erties of complexing with a variety of hydrophobic
compounds [6^8].
CDs are cyclic oligosaccharides formed by the en-
zymatic degradation of amylose [9]. The most com-
mon natural cyclodextrins, K-, L- and Q-CD, are
made up of 6, 7, and 8 glucopyranose units, respec-
tively. They possess complexing properties in aque-
ous media, and are able to take various small organic
molecules like drugs into their hydrophobic cavity
[10]. Consequently, CDs modify the physicochemical
properties of these ‘guest’ molecules by increasing
their solubility in physiological media or their stabil-
ity. These complexing properties of CDs have been
largely applied, particularly in the agrifood industry
to preserve tastes and £avors, in the cosmetic indus-
try to protect active substances against oxidation,
photochemical reactions or losses by volatility, and
in the pharmaceutical sector as excipients to solubi-
lize drugs. The L- and Q-CDs, which have the most
interesting inclusion properties, were used in this
study.
Some years ago, we described the synthesis of a
covalent peptidylcyclodextrin product [6], whose
biological properties were not investigated. A similar
strategy was applied here to synthesize eight com-
pounds corresponding to the grafting of modi¢ed L-
and Q-CD on the neuropeptide substance P (SP) or a
C-terminal fragment, SP(4^11). The rationale for
this design results from the following considerations.
SP is an 11-residue neuropeptide widely distributed
in both the peripheral and central nervous systems
and involved in numerous physiological or patho-
logical processes including pain transmission, neuro-
genic in£ammation [11^13], and, as revealed more
recently, depression and anxiety [14]. These actions
are mediated by the binding of the carboxyamido-
terminal extremity of the peptide to the NK1 recep-
tor (a G-protein coupled receptor), which has thus
long represented an attractive target for drug devel-
opment [15]. The short derivative SP(4^11) corre-
sponds to the last eight residues of the SP sequence
and exhibits almost the same biological properties as
SP. The grafting of CD was achieved on the K- or O-
amino function located on the amino-terminal part
of the peptides, which is known not to be directly
involved in the binding to the NK1 receptor. We
used a cultured cell line stably expressing the re-
combinant human NK1 receptor and developed spe-
ci¢c antibodies directed against (i) L-CD, (ii) Q-CD,
and (iii) the carboxyterminal part of SP. These dif-
ferent tools have proved useful in demonstrating
that the SP peptide antenna is well suited to e⁄-
ciently targeting a carrier component towards cells
bearing the human NK1-speci¢c receptor. On the
other hand, the capability of one of these new com-
pounds to bind the rat NK1 receptor was investi-
gated by performing a competition experiment with
125I-labeled SP, further analyzed by autoradiog-
raphy.
2. Materials and methods
2.1. Materials
L- and Q-CD were from Roquette Fre'res (Lestrem,
France) and Wacker (Munich, Germany), respec-
tively. Unless otherwise stated, all reagents were
from Fluka (France). SP (Arg-Pro-Lys-Pro-Gln-
Gln-Phe-Phe-Gly-Leu-MetNH2) and SP(4^11) (Pro-
Gln-Gln-Phe-Phe-Gly-Leu-MetNH2) were synthe-
sized in the laboratory using a Milligen 9050 appa-
ratus and standard Fmoc chemistry. Peptides were
puri¢ed by means of high-performance liquid chro-
matography (HPLC).
The di¡erent CD^SP and CD^SP(4^11) conjugates
synthesized were: [(L-CD)Arg1, Lys3]^SP; [Arg1,
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(L-CD) Lys3]^SP; [(L-CD)Arg1, (L-CD)Lys3]^SP;
[(Q-CD)Arg1, Lys3]^SP; [Arg1, (Q-CD) Lys3]^SP;
[(Q-CD)Arg1, (Q-CD) Lys3]^SP; [(L-CD)Pro1]^
SP(4^11); [(Q-CD)Pro1]^SP(4^11).
The mono CD^SP adducts are substituted on oth-
er primary amino groups of the SP backbone with a
tri£uoroacetamido group which can be removed by
piperidine treatment.
Puri¢cation of acetylcholinesterase (AChE, EC
3.1.1.7) from electric organs of the electric eel Elec-
trophorus electricus, preparation of the G4 form
used, and measurement of its activity were performed
as previously described [16,17]. Solid-phase EIA was
performed in 96-well microtiter plates (Immunoplate
Maxisorp, Nunc, Denmark) using automatic Titertek
microtitration equipment (washer, dispenser, and
reader) from Labsystems (Les Ulis, France).
Radiolabeled SP (using 125I-Bolton-Hunter reagent
grafted on the N-terminal residue, 74 TBq/mmol)
and myo-[2-3H]inositol (651 GBq/mmol) were from
Amersham, France. Cell culture medium Ham F-12,
fetal calf serum, penicillin, and streptomycin were
from Gibco (Eregny, France). Bacitracin, lithium
chloride (LiCl) and bovine serum albumin (BSA)
were from Sigma. Cell culture plastic dishes were
from Nunc (Roskilde, Denmark).
All reagents used for immunoassays were diluted
in the following bu¡er (EIA bu¡er): 0.1 M potassi-
um phosphate bu¡er (pH 7.4) containing 0.9% NaCl,
1 mM EDTA, 0.1% bovine serum albumin (BSA)
and 0.01% sodium azide. A 10 mM phosphate bu¡er
containing 0.05% Tween 20 was used for all washing
steps.
2.2. Preparation of the enzymatic tracers
L-CD^AChE and Q-CD^AChE conjugates were
prepared as previously described [18,19]. Brie£y,
6-monoamino-L-CD and 6-monoamino-Q-CD were
¢rst reacted with a ten molar excess of SATA in
0.1 M borate bu¡er (pH 9) for 1 h at 22‡C. After
puri¢cation using Sepak cartridges, the thiol function
of SATA-CD was generated using 0.1 M ethanol-
amine, pH 7. Enzymatic tracers were ¢nally pro-
duced by reaction of SH^CD with maleimido groups
previously introduced onto AChE.
Preparation and characterization of the rabbit
anti-L-CD (L1076S7) or anti-Q-CD (L1124S8) poly-
clonal antibodies and the mouse monoclonal anti-SP
antibody SP31 have been previously described
[18^20]. These antibodies were puri¢ed by caprylic
acid precipitation [21]. Antibodies were then labeled
as previously described [22]. Brie£y, pepsin action
allows production of (FabP)2 fragments which were
further reduced using 2-mercaptoethanolamine to
obtain FabP fragments. The thiol groups of FabP
¢nally reacted with the maleimido groups introduced
onto AChE.
All di¡erent tracers were puri¢ed by molecular
sieve chromatography on a Biogel A1.5M column.
2.3. Enzyme immunoassays
Competitive enzyme immunoassays (EIA) for SP,
L-CD and Q-CD have been previously described [18^
20]. These assays were performed in 96-well micro-
titer plates coated with mouse monoclonal anti-rab-
bit IgG antibodies. The total volume of the immuno-
logical reaction was 150 Wl, each component
(enzymatic tracer, diluted rabbit polyclonal antisera
and standards) being added in a 50-Wl volume diluted
in EIA bu¡er. After 18 h incubation at 4‡C, the
plates were washed and the enzyme activity of the
bound immunological complex was revealed by ad-
dition of 200 Wl/well of Ellman reagent. After 2 h of
gentle shaking in the dark at room temperature, the
absorbance at 414 nm in each well was measured
automatically. Results are given in terms of
(B/B0)U100 as a function of the dose (logarithmic
scale), B and B0 representing the bound enzyme ac-
tivity in the presence or absence of competitor, re-
spectively. A linear log-logit transformation was used
to ¢t the standard curve. All experiments were done
in duplicate and quadruplicate for B0.
In addition, novel two-site immunometric assays
were developed for CD^SP compounds. In some of
these assays, the adducts were captured by the
monoclonal anti-SP antibody SP31 coated in 96-
well microtiter plates and revealed using AChE-la-
beled polyclonal L-CD or Q-CD antibodies. In other
assays, the polyclonal antibodies directed against
L-CD or Q-CD were used as capture antibodies in
combination with SP31^AChE conjugate as the trac-
er. These assays were performed sequentially: pepti-
dylcyclodextrin CD^SPs were ¢rst bound by capture
antibodies (18 h, 4‡C). After washing, solid-phase
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bound CD^SP were then revealed (18 h, 4‡C) by the
enzyme conjugate (either SP31^AChE or anti-CD^
AChE).
2.4. Cell cultures and binding assays
CHO cells expressing human NK1 receptor were
cultured in Ham F12 medium supplemented with
10% fetal calf serum, 2 mM glutamine, 100 units/ml
penicillin and 100 Wg/ml streptomycin, at 37‡C in a
5% CO2 humidi¢ed atmosphere. For binding analysis,
CHO cells (105 cells/well) were distributed in 24-well
plates 24 h before the experiments. Cells were washed
three times with Krebs bu¡er (120 mM NaCl, 4.8
mM KCl, 1.2 mM MgSO4, 70 mM NaH2PO4, 1.6
mM CaCl2, 0.04 mM BSA, 30 mg/l bacitracin and
6 g/l glucose) before incubation with [125I]SP (20 000
cpm/well corresponding to 12 pM, 100 Wl of Krebs
bu¡er) and various concentrations of CD^SP deriva-
tives in Krebs bu¡er. The reaction was stopped after
30 min by washing three times with cold Krebs bu¡er.
The cells were lysed with 0.1% Triton X-100 and the
radioactivity was counted. Each point was measured
in triplicate and non-speci¢c binding was determined
in the presence of 1 WM native SP.
2.5. Measurement of phosphatidylinositol hydrolysis
Experiments were carried out as already described
[23]. After labeling with [3H]inositol for 24 h, CHO
cells (2U105 cells/well in 24-well plates) were incu-
bated for 15 min in the presence of various concen-
trations of CD^SP conjugates. After washing, cells
were lysed using a 1% Triton X-100 solution. Un-
reacted radiolabeled phosphatidylinositol was re-
moved from the aqueous cells solution by extraction
with an equal volume of chloroform/methanol (1:2)
mixture. The [3H]inositol phosphates (IP) were then
puri¢ed by ion exchange chromatography. The basal
level of IP production was estimated in the absence
of CD^SP conjugates. Each measurement was per-
formed in triplicate.
2.6. Autoradiography
Three rats were deeply anesthetized with 60 mg/kg
i.p. of pentobarbital (Sano¢, Libourne, France) and
perfused intracardially with 500 ml of 0.9% NaCl
containing 0.1% sodium nitrite as vasodilator. Spinal
cords were rapidly dissected out and frozen in iso-
pentane cooled to 330‡C. Twenty Wm-thick coronal
sections were cut using a cryostat and then mounted
on gelatin-coated slides. The slides were kept at
380‡C until used. The slides were preincubated at
room temperature in a solution of 50 mM Tris
(pH 7.4) and 0.2 g/l bovine serum albumin (BSA)
for 30 min. Slides were then incubated for 2 h in
the same bu¡er solution containing 3 mM MnCl2,
0.125 nM [125I]SP (125I-Bolton Hunter reagent
grafted on the N-terminal residue of SP, Amersham,
France), and a cocktail of peptidase inhibitors con-
taining 20 Wg/ml leupeptin, 0.3 Wg/ml benzamidine,
0.05 Wg/ml bacitracin, 20 Wg/ml chymostatin and 0.03
mg/ml phenylmethylsulfonyl £uoride. Various con-
centrations of CD^SP or cold SP (1036^1039 M)
were added to the incubation medium. Four 30-s
washes in 50 mM Tris (pH 7.4) and 0.2 g/l BSA
were performed at 4‡C. The slides were then dried
with cold air and exposed to 3H-ultro¢lm (Amer-
sham, France) for 3^10 days. Autoradiograms were
developed in Kodak Microdol for 10 min at 20‡C.
They were then digitized using a camera and an IM-
STAR image analysis system using the Starwise soft-
ware.
2.7. Comparison of the stability of SP and
CD^SP products in biological media
SP or CD^SP compounds at a 0.1 Wg/ml ¢nal con-
centration were added to 0.5 ml of freshly collected
rat blood. After incubation at 37‡C, 50-Wl aliquots
were collected at the following times: 0, 10, 30 min,
1, 6, and 24 h. Nine volumes of cold methanol were
immediately added to the sample before centrifuga-
tion (2500 rpm, 10 min). The pellet was discarded
and the supernatant dried under vacuum using a
SpeedVac apparatus (Savant, Farmingdale, NY) be-
fore reconstitution with 500 Wl of EIA bu¡er. This
procedure allowed recovery of more than 95% of the
molecules in the supernatant, which were quanti¢ed
using competitive enzyme immunoassays, as de-
scribed above.
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3. Results
3.1. Synthesis of the di¡erent CD^SP derivatives
The covalent grafting of either L-CD or Q-CD on
SP led to six di¡erent products corresponding to re-
action with (i) the K-NH2 of the peptide
[CD(Arg1)SP], (ii) the O amino function of the Lysyl
residue [CD(Lys3)SP], (iii) both functions simultane-
ously [(CD)2(Arg1, Lys3)]^SP adducts (Fig. 1). For
SP(4^11), only two adducts were synthesized, corre-
sponding to the grafting of L- or Q-CD on the N-
terminal residue (Pro) of the octapeptide. The eight
di¡erent isolated compounds were puri¢ed by means
of HPLC (purity s 95%), and fully characterized by
NMR and mass spectroscopy experiments [24].
3.2. Molecular recognition by speci¢c antibodies
The recognition of the di¡erent synthetic products
by anti-SP and anti-L or Q-CD antibodies was eval-
uated. The polyclonal anti-SP antibodies appeared to
be interesting molecular probes since they were pre-
viously shown to be directed against the 6 carboxy-
terminal residues of SP, which are also directly in-
volved in receptor binding [15]. The standard curves
obtained with the eight compounds are presented in
Fig. 2. As shown in Fig. 2A, all monosubstituted CD
derivatives are recognized by the anti-SP antibodies
and gave parallel curves, although di¡erences were
noted with SP, demonstrating minor structural mod-
i¢cation of the SP backbone. As illustrated in Fig.
2B for the two disubstituted derivatives and in Fig.
2C for the SP(4^11) series, the standard curves ob-
tained for CD derivatives remained parallel to each
other but not to the SP standard curve. It seems that
the grafting of CD on the SP backbone only leads to
minor structural modi¢cations, as revealed by anti-
SP antibody binding. When tested with anti-L-CD or
anti-Q-CD antibodies, the corresponding compounds
were also perfectly recognized (data not shown).
Since these latter polyclonal antibodies have been
characterized as directed against the large secondary
hydroxyl rim mainly involved in the inclusion pro-
cess, these experiments corroborated the NMR re-
sults which demonstrated that the ability of the CD
core of these new compounds to include guest mol-
ecules was largely preserved [24].
3.3. Molecular recognition by human NK1 receptor
Since the previous experiments revealed the struc-
tural integrity of the C-terminal part of SP, an epi-
tope also involved in SP-receptor binding, they sug-
gested that SP^CD conjugates might also be able to
recognize the NK1 receptor.
Fig. 1. Molecular structure of the [(L-CD)Arg1, (L-CD)Lys3]^SP conjugate.
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Using CHO cells expressing recombinant human
NK1-R, the binding e⁄ciency of the di¡erent CD^
SP and CD^SP(4^11) products was evaluated, by
analyzing the speci¢c displacement of iodine-labeled
SP. The results for these di¡erent compounds are
presented in Fig. 3. It appeared that the grafting of
CD on the SP backbone systematically lowered the
a⁄nity of the products by comparison with natural
SP (5.5 nM). As shown in Fig. 3A, L- and Q-mono-
substituted derivatives gave very similar curves, inde-
pendently of the position (K1 or O3) of CD grafting.
However, the size of the CD incorporated appeared
important since L-CD compounds exhibited IC50 val-
ues close to 30 nM while IC50 values for Q-CD prod-
ucts were six times higher (180 nM). However, the
disubstitution tended to reduce this di¡erence (Fig.
3B) since (L-CD)2^SP and (Q-CD)2^SP presented
IC50 values of the same order of magnitude (120
nM versus 180 nM). It appeared also from these
values that the disubstitution decreased the a⁄nity
of the (Q-CD)2^SP component 4-fold compared to
the monosubstitution in the case of L-CD (120 nM
compared to 30 nM) but not in the case of Q-CD
grafting (both values close to 180 nM). Finally, as
shown in Fig. 3C, both the L- and Q-derivatives of SP
(4^11) exhibited a signi¢cantly lower a⁄nity for the
NK1 receptor than SP(4^11) alone (IC50 of 135 and
300 nM, respectively, compared to 85 nM).
3.4. Evaluation of the pharmacological response
induced by these new compounds
The potency of all SP^CD derivatives to trigger a
pharmacological response upon NK1 receptor bind-
ing was investigated by measuring the intracellular
production of phosphatidylinositol. A preliminary
experiment using a saturating 1 WM concentration
of natural SP and of all CD^SP compounds demon-
strated similar kinetics with the same initial slope
and a plateau reached after 30 min of reaction
(data not shown). However, this maximal IP produc-
tion was always lower for CD^SP than for SP alone.
A dose^response study (using 15-min incubation of
the compounds) gave the results shown in Fig. 4. All
compounds were e⁄cient agonists of the NK1 recep-
tor. The di¡erent L- and Q-monosubstituted de-
rivatives exhibited EC50 values ranging from 0.5 to
2 nM, very close to that for natural SP (0.5 nM)
Fig. 2. Immunological cross-reactivities (CR) of CD^SP conju-
gates for polyclonal anti-SP antibodies. CR were measured in
competition enzyme immunoassay (EIA) using AChE^SP as
tracer. Results are expressed as percent of the bound tracer
maximal value (B0) as a function of increasing concentrations
of CD^SP compounds or of free SP. Values correspond to the
mean þ (S.D.) of four determinations. Experiments were carried
out using monoconjugated [Arg1, (L-CD)Lys3]^SP (F), [(L-CD)-
Arg1, Lys3]^SP (R), [Arg1, (Q-CD)Lys3]^SP (E), [(Q-CD)Arg1,
Lys3]^SP (O) and SP (S), in panel A; diconjugated [(L-CD)-
Arg1, (L-CD)Lys3]^SP (b), [(Q-CD)Arg1, (Q-CD)Lys3]^SP (a)
and SP (S) in panel B; [(L-CD)Pro1]^SP(4^11) (8), [(Q-CD)-
Pro1]^SP(4^11) (W) and SP(4^11) (P) in panel C.
BBAMCR 14792 17-12-01 Cyaan Magenta Geel Zwart
C. Pe¤an et al. / Biochimica et Biophysica Acta 1541 (2001) 150^160 155
(Fig. 4A). Addition of one L- or Q-CD to SP did not
seem to grossly modify the e⁄ciency of IP produc-
tion, since maximal levels appeared very similar for
all compounds and only slightly reduced (10^15%)
compared to the maximal e¡ect of SP. The results,
however, were di¡erent in the case of disubstituted
compounds as shown in Fig. 4B: although EC50 val-
ues for these compounds were similar to those mea-
sured for their monosubstituted counterparts
(around 2 nM), a large decrease in maximal IP pro-
duction was observed, and their maximal e¡ects re-
mained considerably lower than those observed with
monosubstituted conjugates (30% and 50% decrease
for (L-CD)2 and (Q-CD)2 compounds, respectively).
Fig. 4. Inositol phosphate (IP) production as a function of in-
creasing concentrations of CD^SP conjugates in CHO cells ex-
pressing the human NK1 receptor. Values correspond to the
mean þ S.D. of six determinations. Experiments were carried
out using increasing concentrations of monoconjugated [Arg1,
(L-CD)Lys3]^SP (F), [(L-CD)Arg1, Lys3]^SP (R), [Arg1, (Q-CD)
Lys3]^SP (E), [(Q-CD)Arg1, Lys3]^SP (O) and SP (S) in panel
A; diconjugated [(L-CD)Arg1, (L-CD)Lys3]^SP (b), [(Q-CD)-
Arg1, (Q-CD)Lys3]^SP (a) and SP (S) in panel B.
Fig. 3. Inhibition by CD^SP conjugates of [125I]SP binding to
human NK1 receptor expressed in CHO cells. Results are ex-
pressed in percent of the maximal binding value of iodinated
SP. Values correspond to the mean þ S.D. of six determinations.
Experiments were carried out using increasing concentrations of
monoconjugated [Arg1, (L-CD)Lys3]^SP (F), [(L-CD)Arg1,
Lys3]^SP (R), [Arg1, (Q-CD)Lys3]^SP (E), [(Q-CD)Arg1, Lys3]^
SP (O) and SP (S), in panel A; diconjugated [(L-CD)Arg1,
(L-CD)Lys3]^SP (b), [(Q-CD)Arg1, (Q-CD)Lys3]^SP (a) and SP
(S) in panel B; [(L-CD)Pro1]^SP(4^11) (8), [(Q-CD)Pro1]^
SP(4^11) (7) and SP(4^11) (P) in panel C.
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3.5. [Arg1, (Q-CD)Lys3]^SP recognizes the NK1 rat
receptor in vitro: autoradiography analysis
Autoradiography of rat spinal cord sections dem-
onstrated a high density of binding sites in all regions
known to be rich in NK1 receptors. The most intense
labeling was observed in the dorsal horn, particularly
in the medial part of the super¢cial layers and
around the central canal. When CD^SP was added
to the incubation medium, a dose-dependent compe-
tition with [125I]SP was observed as shown on serial
sections of the spinal cord by the decrease in labeling
intensity (Fig. 5). A quantitative analysis, performed
after optical density measurements in lamina I of the
dorsal horn (i.e., the region most intensely labeled by
[125I]SP), revealed that the potency of CD^SP in
competing with [125I]SP was only slightly diminished
(by a factor of 10^50) compared to that of SP alone
(Fig. 5D). Using this CD^SP product, the IC50 value
obtained here on the rat NK1 receptor was close to
the value calculated in binding experiments on CHO
cells expressing the human receptor, suggesting that
this CD^SP conjugate exhibits a similar a⁄nity for
both receptors.
3.6. Stability of CD^SP compounds in
biological media
The competitive immunoassays previously de-
scribed can only check one part of the bifunctional
molecules, i.e., either the SP or the CD moiety, and
are therefore unsuitable for measuring the bioavail-
Fig. 5. Digitized autoradiograms of serial coronal sections of the rat cervical spinal cord incubated in 0.1 nM [125I]SP alone (A) and
increasing concentrations of [Arg1, (Q-CD)Lys3]^SP (B: 1038 M; C: 1037 M). The dorsal horn and the region around the ependymal
canal are highly labeled (in red). A dose-dependent decrease in [125I]SP labeling is observed after incubation with [Arg1, (Q-CD)Lys3]^
SP (scale bar = 750 Wm). (D) Inhibition of [125I]SP by [Arg1, (Q-CD)Lys3]^SP (full line) and SP (dotted line) as a function of the con-
centration (in molarity). Binding is indicated in optical density measured in lamina I of the cervical dorsal horn. Values are the means
of four or more determinations for each set of experimental conditions (S.E.M. are indicated).
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ability of CD^SP compounds in biological media,
especially if degradation is likely to occur rapidly.
For this reason, we also developed two-site immuno-
metric assays for measurement of the compounds
exclusively in their intact form. Due to the use of
reagents in excess, these novel assays appeared
more sensitive than competitive assays. Four di¡er-
ent assays using either the anti-L or anti-Q-CD poly-
clonal antibodies as capture antibodies in combina-
tion with AChE-labeled anti-SP mAb SP31 as tracer,
or vice versa, were developed. All these assays had a
detection limit close to 5 pg/ml for the eight prod-
ucts, as illustrated for [(Q-CD)Arg1, Lys3]^SP and
[Arg1, (Q-CD)Lys3]^SP in Fig. 6A. This assay was
further used to evaluate the stability of the com-
pound in plasma. As shown in Fig. 6B, the adduct
proved to be fully protected from enzymatic degra-
dation for at least 1 h, whereas natural SP was com-
pletely degraded after 30 min. For longer incubation
times, a half-life of 6 h was calculated for the
[(Q-CD)Arg1, Lys3]^SP and for the [Arg1, (Q-CD)
Lys3]^SP compounds (data not shown).
4. Discussion
The present paper documents the conformational
and pharmacological properties of eight new pepti-
dylcyclodextrin adducts, each comprising a L- or Q-
cyclodextrin part and a peptide moiety constituted
by the neuropeptide substance P or a shorter deriv-
ative, substance P (4^11). All these new compounds
were fully characterized by means of NMR and high-
resolution mass spectrometry in a previous study
[24]. Since these conjugates were designed speci¢cally
to target the human NK1 receptor, we ¢rst investi-
gated the possible structural changes of the peptide
induced by grafting CDs on SP. Speci¢c antibodies
directed against either SP or CDs moieties were thus
used as molecular probes to estimate conformational
modi¢cations. We ¢rst evaluated the recognition
properties of an antibody speci¢cally directed against
the carboxyamido extremity of SP, known to be di-
rectly involved in the binding of the ligand to the
NK1 receptor [11,25]. These polyclonal antibodies
clearly do not mimic the real interactions of SP
with the receptor, but can e⁄ciently detect structural
modi¢cations which could further impair proper
binding of our conjugates to the receptor. Interesting
data on cyclodextrin structure can be obtained by
analyzing the interaction of speci¢c anti-L or anti
Q-CD antibodies with these new compounds.
The di¡erent CD^SP conjugates were e⁄ciently
Fig. 6. Immunometric assays of monoconjugated Q-CD^SP.
Standard curves (A) were obtained using a rabbit anti-SP poly-
clonal antibody as the capture antibody, anti Q-CD antibodies
labeled with AChE as the enzymatic tracer and increasing con-
centrations of [(Q-CD)Arg1, Lys3]^SP (O) and [Arg1, (Q-CD)-
Lys3]^SP (E) as standards. Results are expressed in absorbance
units measured after 1 h incubation. In panel B, this assay was
used to compare the stability of [(Q-CD)Arg1, Lys3]^SP (O),
[Arg1, (Q-CD)Lys3]^SP (E) and SP (S) in rat plasma. SP or
CD^SP conjugates were added to plasma at time 0 at a ¢nal
concentration of 0.1 Wg/ml and the remaining concentrations
were estimated by the immunometric assay after 0, 10, 30 and
60 min incubation times. Values are expressed in percent of the
initial concentration and are mean þ S.D. of four determina-
tions.
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recognized by anti-SP antibodies during competitive
assays, thus demonstrating that the C-terminal con-
formation of the peptide was not greatly modi¢ed by
the grafting of CD on the N-terminal part. This ob-
servation applied to mono-CD derivatives independ-
ently of the amino function involved, i.e., K-NH2 or
O-NH2 of Lys3 residue, and of the size of the CD. It
also applied to di-CD derivatives, indicating that the
two bulky grafted groups did not alter the recogni-
tion of the conjugates by anti-SP antibodies through
steric hindrance. Conversely, competitive assays per-
formed using anti-CD antibodies also revealed the
perfect recognition of the CD. Since these antibodies
are directed against the secondary hydroxyl rim of
CDs involved in the inclusion process, these latter
results suggest that the inclusion properties of our
compounds were not a¡ected by chemical treatments.
The two-site immunometric assays presented here
were based on the simultaneous use of two di¡erent
antibodies speci¢cally directed against the peptide
and the CD parts of the molecule and were thus
completely speci¢c for the intact molecule. Clearly,
these very sensitive and speci¢c assays will be of
great value in studying the bioavailability of injected
compounds. In this regard, immunometric assays
demonstrated that SP^CD conjugates are consider-
ably more stable in biological media than SP alone, a
very important result allowing further in vivo experi-
ments. This increased stability suggests that the
grafting of CD on SP amino functions partly pro-
tects the peptide from proteolysis through a steric
hindrance, probably a¡ecting either the binding to
the enzyme or the catalytic process itself.
In vitro experiments using CHO transfected cells
¢rst demonstrated that all conjugates e⁄ciently
bound the human NK1 receptor. However, a signi¢-
cant decrease in a⁄nity was noted, compared to SP,
which was particularly marked for the mono-Q-CD
derivatives and for disubstituted conjugates. These
results are not surprising since it is now well estab-
lished that the N-terminal part of SP, although not
directly interacting with the receptor, is also involved
in the recognition by the NK1 receptor [26]. More-
over, the decrease does not seem to be related to the
position of the substitution but rather to the size of
the CD grafted (Q-CD being larger than L-CD),
which is also supported by the fact that disubstituted
conjugates are less e⁄ciently recognized compounds.
Contrary to what was observed for SP, the mono-
conjugation of CD to the shorter peptide SP(4^11)
did not reduce the a⁄nity of the octapeptide, which
nonetheless remained signi¢cantly lower than that of
full-length SP.
Measurement of IP3 production in intact CHO
cells showed that the CD^SP conjugates induced sec-
ond messenger production, thus demonstrating their
fully active agonist action. All the di¡erent monosub-
stituted derivatives exhibited agonist properties close
to those of natural SP, both in terms of maximal
e¡ect and EC50 values. Although the disubstituted
derivatives had similar EC50 values, they proved to
be less e⁄cient for IP3 production, apparently due to
the size of the CD grafted. The binding results (IC50)
and IP measurements (EC50) thus exhibited no direct
relation, suggesting that the structural requirements
for agonist binding are not identical to those for
agonist activity. Interestingly, a similar absence of
correlation between the ability of peptidylcyclodex-
trins to recognize a speci¢c receptor and to induce
second messenger production have recently been re-
ported for L-CD^gastrin conjugates [8].
Autoradiography experiments on rat spinal cord
sections, using [125I]SP for labeling the NK1 receptor
and a Q-CD^SP derivative as a competitor, further
showed that this derivative binds the rat receptor, as
e⁄ciently as the human counterpart. This observa-
tion is of particular interest in view of future in vivo
studies on this animal model.
Indeed, the next step will be to evaluate, through
experiments carried out in the rat, the in vivo recog-
nition of NK1 receptor by these conjugates. Prelimi-
nary studies, using immunocytochemistry at both
light and electron microscopy levels after intracere-
bral injection of CD^SP adduct, lead to promising
results (data not shown). Other important points
which need further investigations in vivo should be
(i) to compare di¡erent routes of CD^SP administra-
tion, (ii) to compare the pharmacokinetics of drugs
included into CD^SP conjugates or administered
alone, and (iii) to analyze the fate of injected materi-
al, i.e., the potential ability for these new compounds
to penetrate inside the targeted cells on the one hand
and to cross the blood^brain barrier on the other
hand. Some of these experiments are presently in
progress in our laboratories.
As regards potential clinical applications, we be-
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lieve that SP^CD conjugates could be of special in-
terest in numerous in£ammatory diseases of periph-
eral organs involving an upregulation of NK1-R
[14,27], in which receptors could be easily and rap-
idly accessible after oral or i.v. administration of the
conjugates. Pharmaceutical preparations, involving
drug inclusions in free cyclodextrins, are already cur-
rently used, for example in the ¢eld of non-steroidal
anti-in£ammatory treatments: both solubility and
bioavailability of the drugs can be greatly increased
by inclusion [28,29], thus considerably reducing the
drug dose administered. In this connection, the use
of a drug included in a cyclodextrin speci¢cally tar-
geted towards a peptide receptor-bearing cell consti-
tutes a promising way of further reducing the drug
dose, thus resulting in more e⁄cient treatments with
minimal side e¡ects.
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